Details of the Drug Reposition

General Information of This Drug (ID: DM958QB)

Drug Name
Ripretinib   DM958QB
Synonyms
1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastrointestinal stromal tumour DIS6TJYS 2B5B Approved [1]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioma DIS5RPEH 2A00.0 Phase 1 [2]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Systemic mastocytosis DISNQ2OY 2A21.0 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)